Metabolism and action of purine nucleoside analogs
W Plunkett, PP Saunders - Pharmacology & therapeutics, 1991 - Elsevier
W Plunkett, PP Saunders
Pharmacology & therapeutics, 1991•ElsevierRecent investigations have identified many new purine nucleoside analogs that act as
antimetabolites. This article focuses on the metabolism and mechanisms of action of
tiazofurin, 3-deazaguanosine, neplanocin A, arabinosyladenine in combination with
inhibitors of adenosine deaminase, arabinosyl-2-fluoroadenine, and 2-chloro-2′-
deoxyadenosine, drugs that are either currently being evaluated in clinical trials or are close
to that stage. The diverse metabolic requirements for activation, unique mechanisms of …
antimetabolites. This article focuses on the metabolism and mechanisms of action of
tiazofurin, 3-deazaguanosine, neplanocin A, arabinosyladenine in combination with
inhibitors of adenosine deaminase, arabinosyl-2-fluoroadenine, and 2-chloro-2′-
deoxyadenosine, drugs that are either currently being evaluated in clinical trials or are close
to that stage. The diverse metabolic requirements for activation, unique mechanisms of …
Abstract
Recent investigations have identified many new purine nucleoside analogs that act as antimetabolites. This article focuses on the metabolism and mechanisms of action of tiazofurin, 3-deazaguanosine, neplanocin A, arabinosyladenine in combination with inhibitors of adenosine deaminase, arabinosyl-2-fluoroadenine, and 2-chloro-2′-deoxyadenosine, drugs that are either currently being evaluated in clinical trials or are close to that stage. The diverse metabolic requirements for activation, unique mechanisms of action, and differential biological activities of these compounds are characterized and evaluated for prospective therapeutic application.
Elsevier